The bond we form with our furry friends is indescribable. Seeing them age over time is never easy, but help may be at hand with Aaron Hirschhorn’s innovative idea. His business is Gallant, a stem cell treatment service for dogs. Similar to human stem cell treatment, this practice allows for your dog’s young stem cells to be stored, which can later be used to alleviate ailments and injuries. With a growing customer base and continued innovations, Gallant Pet has amassed a significant net worth in recent years.
Who is the Gallant Pet?
Gallant Pet is a company that provides stem cell banking services for dogs and other pets. Its core business model involves collecting and cryogenically storing stem cells from a pet’s reproductive tissues during a routine spay or neuter procedure. These stored stem cells can then treat injuries, illnesses, or age-related conditions the pet may develop. Gallant aims to give pet owners peace of mind and the ability to utilize regenerative medicine to improve their companion’s quality of life.
Who Is The Founder Of Gallant Pet?
Aaron Hirschhorn, an entrepreneur with a background in the pet services industry, founded Gallant Pet. Before launching Gallant, Hirschhorn founded and grew a successful dog daycare and boarding company called DogVacay, which eventually merged with a competitor to become Rover. Hirschhorn’s experience with stem cell therapy treating his chronic back pain and seeing his dog struggle with arthritis inspired him to create Gallant and bring this innovative technology to the pet market.
| Founder | Aaron Hirschhorn |
|---|---|
| Business | Stem cell treatment service for dogs |
| Founding Year | Founded after experience with my own dog’s health issues |
| Service Description | Stores young stem cells from reproductive organs for future medical use |
| Patents | Holds four patents related to isolating stem cells from reproductive tissues |
| Launch Details | Featured on Shark Tank Season 11, Episode 8 in 2019 |
| Investment Sought | $500,000 for 2% equity |
| Deal on Shark Tank | Lori Grenier and Anne Wojcicki offered $500,000 for 5% equity, but the deal was not closed. |
How Was The Shark Tank Pitch Gallant Pet?
In 2019, Aaron Hirschhorn brought Gallant Pet to the Shark Tank investors seeking a $500,000 investment in exchange for a 2% equity stake, valuing the company at $25 million. The sharks were initially skeptical of the valuation, as Gallant had yet to launch its consumer-facing business. However, Hirschhorn impressed them with Gallant’s four patents covering the stem cell extraction and storage process. After some negotiation, Hirschhorn struck a deal with Lori Greiner and Anne Wojcicki, who invested $500,000 for a 5% stake in the company.
Gallant Pet Shark Tank Update:
The Shark Tank deal with Grenier and Wojcicki ultimately did not close, but the exposure from the show still provided a significant boost to Gallant Pet’s business. The company could attract new customers and continue growing its operations without the shark investment. Gallant also expanded its services to include stem cell banking for cats, horses, and other pets beyond just dogs.
| Post-Show Developments | Gallant expanded to include cats and horses in its services |
|---|---|
| Financial Strategy | Implemented a higher pricing structure to ensure profitability |
| Acquisition | Acquired vet tech company Cook-Regentec in late 2019 |
| Tragic Event | Founder Aaron Hirschhorn passed away in March 2021 |
| Leadership Transition | Linda Black assumed the CEO role after Hirschhorn’s death |
What Happened To Gallant Pet After Shark Tank?
Following the Shark Tank appearance, Gallant Pet continued to thrive, though it faced a tragic setback in 2021 with the unexpected passing of founder Aaron Hirschhorn. Hirschhorn died in a boating accident at the age of 42. The company’s leadership transitioned to President and Chief Scientific Officer Linda Black, who has worked to uphold Hirschhorn’s vision for Gallant. The business has remained operational, providing pet stem cell banking services to customers across the United States.
Gallant Pet Net Worth:
As of 2022, Gallant Pet is estimated to have a net worth of approximately $7 million. The company has continued to grow its customer base and revenue, with estimated annual revenues of around $5 million. Gallant’s unique business model of charging both one-time setup fees and recurring annual storage fees has allowed it to maintain solid profit margins despite the significant research and development costs involved in advancing stem cell technology for pets.
Gallant Pet Growth and Operations:
Since its founding, Gallant Pet has expanded its operations to serve customers in all 50 U.S. states. The company has diversified its service offerings beyond just dogs, now providing stem cell banking for cats, horses, and other companion animals. Gallant operates an FDA-approved laboratory facility that processes and cryogenically stores the collected stem cell samples. The company continues to invest heavily in research and development to improve the efficacy and applications of its regenerative medicine technologies for pets.
| Current Offerings | Various price plans: yearly, monthly, and lifetime memberships |
|---|---|
| Service Availability | Available in all 50 states |
| Estimated Revenue | $5 million annual revenue (as of 2022) |
| Company Valuation | $7 million (as of 2022) |
| Social Media Presence | Active on Instagram, less active on Facebook and Twitter |
| Media Coverage | Featured in Forbes, Daily Mail, TechCrunch |
Gallant Pet Marketing and Sales:
Gallant Pet has primarily focused its marketing efforts on digital channels, utilizing its website, social media platforms, and partnerships with veterinary clinics to reach prospective customers. The company positions itself as a pet stem cell therapy leader, educating consumers on the benefits and science behind its services. Gallant’s sales model includes various pricing tiers, from one-time setup fees to annual storage plans, making its services accessible to many pet owners.
Gallant Pet Social Media Presence:
Gallant Pet maintains an active presence on social media, primarily on platforms like Instagram and Facebook. The company uses these channels to share educational content, customer testimonials, and updates on its latest innovations. While Gallant’s social media posting frequency has varied over time, it remains an essential avenue for the company to engage with its target audience of pet owners and build brand awareness.
Gallant Pet Interesting Facts:
- Gallant Pet was founded by Aaron Hirschhorn, who previously built and sold the successful dog daycare company DogVacay.
- The company’s technology is based on four patents covering the isolation and storage of stem cells from pet reproductive tissues.
- Gallant now offers stem cell banking services for cats, horses, and other companion animals in addition to dogs.
- Tragically, Gallant founder Aaron Hirschhorn passed away in a boating accident in 2021 at the age of 42.
- Despite this setback, the company has continued to operate and grow under the leadership of Linda Black, President and chief scientific officer.
What’s Next For Gallant Pet?
With the continued advancements in regenerative medicine, Gallant Pet is poised to play a significant role in the future of pet healthcare. The company will likely focus on expanding its customer base, improving its service offerings, and investing in research and development to stay at the forefront of animal stem cell technology. As awareness and adoption of pet stem cell therapy grows, Gallant Pet has the potential to become an industry leader and expand its reach both domestically and internationally.
Final Words:
Gallant Pet’s journey from a Shark Tank pitch to a growing, profitable business with a multi-million dollar net worth is a testament to the power of innovative thinking and a deep commitment to improving the lives of pets and their owners. Despite the tragic loss of its founder, the company has remained resilient and continues to push the boundaries of what’s possible in animal regenerative medicine. As Gallant Pet looks to the future, its potential to transform pet healthcare and bring new hope to beloved companions is genuinely inspiring.
Table of Contents